EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+11.07%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.1B
AUM Growth
-$1.95B
(-64%)
Cap. Flow
-$2.1B
Cap. Flow
% of AUM
-190.3%
Top 10 Holdings %
Top 10 Hldgs %
55.43%
Holding
359
New
34
Increased
188
Reduced
93
Closed
36
Top Buys
| 1 |
STAAR Surgical
STAA
|
$42.6M |
| 2 |
Sea Limited
SE
|
$22.9M |
| 3 |
Mercado Libre
MELI
|
$19.7M |
| 4 |
NIO
NIO
|
$19.6M |
| 5 |
Meta Platforms (Facebook)
META
|
$16.1M |
Top Sells
| 1 |
Alibaba
BABA
|
$1.32B |
| 2 |
JD.com
JD
|
$334M |
| 3 |
Baidu
BIDU
|
$314M |
| 4 |
NetEase
NTES
|
$202M |
| 5 |
Trip.com Group
TCOM
|
$95M |
Sector Composition
| 1 | Consumer Discretionary | 35.58% |
| 2 | Technology | 17.59% |
| 3 | Communication Services | 16.9% |
| 4 | Healthcare | 11.23% |
| 5 | Real Estate | 6.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Alkermes
ALKS
$4.77B
| $475K | 0.04% |
15,946
+4,943
| +45% | +$147K |
|
152
Sarepta Therapeutics
SRPT
$1.9B
| $475K | 0.04% |
6,333
+2,887
| +84% | +$217K |
|
153
BridgeBio Pharma
BBIO
$9.75B
| $472K | 0.04% |
51,948
+20,684
| +66% | +$188K |
|
154
BioCryst Pharmaceuticals
BCRX
$1.73B
| $470K | 0.04% |
44,408
+27,767
| +167% | +$294K |
|
155
Palo Alto Networks
PANW
$128B
| $470K | 0.04% |
5,706
+144
| +3% | +$11.9K |
|
156
United Therapeutics
UTHR
$17.3B
| $468K | 0.04% |
1,985
+434
| +28% | +$102K |
|
157
Ionis Pharmaceuticals
IONS
$9.46B
| $466K | 0.04% |
12,597
+4,263
| +51% | +$158K |
|
158
Editas Medicine
EDIT
$218M
| $465K | 0.04% |
39,341
+21,529
| +121% | +$254K |
|
|
BPMC
159
DELISTED
Blueprint Medicines
BPMC
| $460K | 0.04% |
9,109
+4,411
| +94% | +$223K |
|
160
Emergent Biosolutions
EBS
$414M
| $454K | 0.04% |
14,640
+7,286
| +99% | +$226K |
|
161
Natera
NTRA
$22.9B
| $454K | 0.04% |
12,803
+5,921
| +86% | +$210K |
|
162
Veracyte
VCYT
$2.41B
| $454K | 0.04% |
22,816
+11,540
| +102% | +$230K |
|
163
Neurocrine Biosciences
NBIX
$13.6B
| $453K | 0.04% |
4,643
+1,638
| +55% | +$160K |
|
164
Arcus Biosciences
RCUS
$1.21B
| $450K | 0.04% |
17,775
+9,670
| +119% | +$245K |
|
165
Xcel Energy
XEL
$42.4B
| $445K | 0.04% |
6,283
+163
| +3% | +$11.5K |
|
|
BHVN
166
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $443K | 0.04% |
3,039
+780
| +35% | +$114K |
|
167
Idexx Laboratories
IDXX
$50.7B
| $442K | 0.04% |
1,259
+69
| +6% | +$24.2K |
|
168
Halozyme
HALO
$8.66B
| $440K | 0.04% |
10,000
+2,274
| +29% | +$100K |
|
169
Roper Technologies
ROP
$56.5B
| $440K | 0.04% |
+1,115
| New | +$440K |
|
170
Bank of America
BAC
$373B
| $438K | 0.04% |
14,078
+30
| +0.2% | +$933 |
|
171
DexCom
DXCM
$31.3B
| $438K | 0.04% |
5,872
+360
| +7% | +$26.9K |
|
172
Cytokinetics
CYTK
$6.01B
| $436K | 0.04% |
11,086
+3,932
| +55% | +$155K |
|
|
CCXI
173
DELISTED
ChemoCentryx, Inc.
CCXI
| $433K | 0.04% |
17,480
+6,171
| +55% | +$153K |
|
174
Ironwood Pharmaceuticals
IRWD
$167M
| $430K | 0.04% |
37,265
+14,279
| +62% | +$165K |
|
175
Cintas
CTAS
$82.9B
| $428K | 0.04% |
4,588
| – | – |
|